文献速递腹部CT

用于鉴别慢性胰腺炎患者中肿块型慢性胰腺炎与胰腺导管腺癌的两种列线图

Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis.
PubMed 文献 · Eur Radiol · 2022-04-08

本回顾性研究纳入138例经组织病理学确诊的肿块型慢性胰腺炎或胰腺导管腺癌患者,基于训练队列103例和验证队列35例构建并验证CT列线图与影像组学列线图。CT列线图训练队列AUC为0.87、验证队列AUC为0.94;影像组学列线图训练队列AUC为0.91、验证队列AUC为0.93。决策曲线分析显示CT列线图阈值概率0.05-0.85、影像组学列线图阈值概率>0.05时患者可获益。

要点

  • CT列线图鉴别肿块型慢性胰腺炎与胰腺导管腺癌:训练队列AUC 0.87,验证队列AUC 0.94。
  • 影像组学列线图鉴别两者:训练队列AUC 0.91,验证队列AUC 0.93。
  • 决策曲线分析示阈值概率0.05-0.85(CT列线图)和>0.05(影像组学列线图)时患者可获益。

核心结论

  • 两种列线图在慢性胰腺炎患者中能较准确地区分肿块型慢性胰腺炎与胰腺导管腺癌,可能有助于优化慢性胰腺炎患者胰腺肿物的管理。

研究设计与样本

  • 回顾性研究,纳入138例经组织病理学确诊的肿块型慢性胰腺炎或胰腺导管腺癌患者,训练队列103例连续患者、验证队列35例连续患者,由两名放射科医师依据预设标准分析原始横断面CT图像,构建CT列线图与基于CT的影像组学列线图。

诊断标准与关键数值

  • CT列线图鉴别肿块型慢性胰腺炎与胰腺导管腺癌的训练队列AUC为0.87、验证队列AUC为0.94;影像组学列线图训练队列AUC为0.91、验证队列AUC为0.93;决策曲线分析示CT列线图阈值概率0.05-0.85、影像组学列线图阈值概率>0.05时患者可获益。

临床应用与阅片要点

  • 作者认为两种列线图能较准确地区分慢性胰腺炎患者的肿块型慢性胰腺炎与胰腺导管腺癌,并可能用于监测慢性胰腺炎患者的癌症风险、优化胰腺肿物管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop and validate a CT nomogram and a radiomics nomogram to differentiate mass-forming chronic pancreatitis (MFCP) from pancreatic ductal adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP).

METHODS: In this retrospective study, the data of 138 patients with histopathologically diagnosed MFCP or PDAC treated at our institution were retrospectively analyzed. Two radiologists analyzed the original cross-sectional CT images based on predefined criteria. Image segmentation, feature extraction, and feature reduction and selection were used to create the radiomics model. The CT and radiomics models were developed using data from a training cohort of 103 consecutive patients. The models were validated in 35 consecutive patients. Multivariable logistic regression analysis was conducted to develop a model for the differential diagnosis of MFCP and PDAC and visualized as a nomogram. The nomograms' performances were determined based on their differentiating ability and clinical utility.

RESULTS: The mean age of patients was 53.7 years, 75.4% were male. The CT nomogram showed good differentiation between the two entities in the training (area under the curve [AUC], 0.87) and validation (AUC, 0.94) cohorts. The radiomics nomogram showed good differentiation in the training (AUC, 0.91) and validation (AUC, 0.93) cohorts. Decision curve analysis showed that patients could benefit from the CT and radiomics nomograms, if the threshold probability was 0.05-0.85 and > 0.05, respectively.

CONCLUSIONS: The two nomograms reasonably accurately differentiated MFCP from PDAC in patients with CP and hold potential for refining the management of pancreatic masses in CP patients.

KEY POINTS: • A CT nomogram and a computed tomography-based radiomics nomogram reasonably accurately differentiated mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis (CP). • The two nomograms can monitor the cancer risk in patients with CP and hold promise to optimize the management of pancreatic masses in patients with CP.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Meng Y, Li Q, et al. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis. Eur Radiol. 2022. PMID: 35394185. doi:10.1007/s00330-022-08698-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。